Johnson & Johnson reports long-term efficacy for oral psoriasis drug Icotyde

Johnson & Johnson has reported long-term results from its Phase 3 ICONIC-LEAD trial for icotrokinra (Icotyde), an oral peptide designed to treat moderate-to-severe plaque psoriasis. Data presented through week 112 showed that at least 72% of treated participants maintained a PASI 90 response from week 64 through week 112.

In addition to skin clearance, at least 70% of participants achieved an Investigator’s Global Assessment (IGA) score of 0/1 during the same period. The trial also indicated that 44% of patients achieved PASI 100, representing complete skin clearance, while 78% of patients experienced sustained, clinically meaningful improvement in itch.

The study enrolled 684 adults and adolescents, including 66 adolescents. Safety findings through week 112 remained consistent with the drug’s established profile, with no new safety signals identified. The trial also examined retreatment responses, finding that 85% of patients who had previously withdrawn from the drug regained PASI 90 within 24 weeks of restarting treatment.